Press releases - 2025年10月3日 9:00 CET
Zinzino AB (publ.): Preliminary Sales Report Q3 2025
Zinzino group revenue increased 48% in Q3, compared with the previous year.
The revenue in September 2025 for Zinzino's sales markets increased by 53 % and amounted to SEK 273.5 (178.7) million. Faun Pharma's external sales decreased and amounted to SEK 3.7 (5.8) million. Overall, the Group increased revenues by 50% to SEK 277.2 (184..5) million compared with the previous year.
Revenue in Zinzino's sales markets increased by 54 % in the third quarter of 2025 compared with the same period last year and amounted to SEK 777.3 (504.4) million. Total revenues in the Group increased by 48% in the third quarter and amounted to SEK 786.7 (532.8) million.
Accumulated revenue for January – September 2025 increased by 54% to SEK 2,304.9 (1,494.3) million. 
 
Revenues were distributed as follows:
 
| 
			 Regions, mSEK  | 
			
			 25-Sep  | 
			
			 24-Sep  | 
			
			 Change  | 
			
			 Q3 2025  | 
			
			 Q3 2024  | 
			
			 Change  | 
			
			 YTD 2025  | 
			
			 YTD 2024  | 
			
			 Change  | 
		
| 
			 The Nordics  | 
			
			 26.5  | 
			
			 25.4  | 
			
			 4%  | 
			
			 79.6  | 
			
			 72.5  | 
			
			 10%  | 
			
			 235.1  | 
			
			 214.0  | 
			
			 10%  | 
		
| 
			 Central Europe  | 
			
			 93.8  | 
			
			 48.7  | 
			
			 93%  | 
			
			 242.8  | 
			
			 138.6  | 
			
			 75%  | 
			
			 657.9  | 
			
			 394.4  | 
			
			 67%  | 
		
| 
			 East Europe  | 
			
			 29.4  | 
			
			 28.3  | 
			
			 4%  | 
			
			 89.7  | 
			
			 88.3  | 
			
			 2%  | 
			
			 276.2  | 
			
			 279.9  | 
			
			 -1%  | 
		
| 
			 South & West Europe  | 
			
			 50.1  | 
			
			 38.0  | 
			
			 32%  | 
			
			 137.2  | 
			
			 104.2  | 
			
			 32%  | 
			
			 399.2  | 
			
			 264.5  | 
			
			 51%  | 
		
| 
			 The Baltics  | 
			
			 8.9  | 
			
			 7.2  | 
			
			 24%  | 
			
			 28.6  | 
			
			 21.9  | 
			
			 31%  | 
			
			 85.3  | 
			
			 69.4  | 
			
			 23%  | 
		
| 
			 North America  | 
			
			 41.3  | 
			
			 20.3  | 
			
			 103%  | 
			
			 129.8  | 
			
			 52.6  | 
			
			 147%  | 
			
			 382.1  | 
			
			 134.0  | 
			
			 185%  | 
		
| 
			 Asia-Pacific  | 
			
			 21.6  | 
			
			 9.6  | 
			
			 125%  | 
			
			 63.7  | 
			
			 22.3  | 
			
			 186%  | 
			
			 212.7  | 
			
			 47.5  | 
			
			 348%  | 
		
| 
			 Africa  | 
			
			 1.9  | 
			
			 1.2  | 
			
			 58%  | 
			
			 5.8  | 
			
			 4.0  | 
			
			 46%  | 
			
			 16.0  | 
			
			 10.9  | 
			
			 47%  | 
		
| 
			 Zinzino  | 
			
			 273.5  | 
			
			 178.7  | 
			
			 53%  | 
			
			 777.3  | 
			
			 504.4  | 
			
			 54%  | 
			
			 2264.5  | 
			
			 1414.6  | 
			
			 60%  | 
		
| 
			 Faun Pharma  | 
			
			 3.7  | 
			
			 5.8  | 
			
			 -36%  | 
			
			 9.4  | 
			
			 28.4  | 
			
			 -67%  | 
			
			 40.4  | 
			
			 79.7  | 
			
			 -49%  | 
		
| 
			 Zinzino Group  | 
			
			 277.2  | 
			
			 184.5  | 
			
			 50%  | 
			
			 786.7  | 
			
			 532.8  | 
			
			 48%  | 
			
			 2304.9  | 
			
			 1494.3  | 
			
			 54%  | 
		
Countries in regions:
-The Nordics: Denmark, Faroe Island, Finland, Iceland, Norway, Sweden
-Central Europe: Austria, Germany, Switzerland
-East Europe: Czech Republic, Slovakia, Hungary, Poland, Romania
-South & West Europe: Cyprus, France, Greece, Italy, Luxembourg, Malta, Netherlands, Slovenia, Spain, United Kingdom, Belgium, Ireland, Serbia, Turkey, Canary Islands
-The Baltics: Estonia, Latvia, Lithuania
-North America: Canada, USA, Mexico
-Asia-Pacific: Australia, New Zealand, Hong Kong, India, Malaysia, Singapore, Taiwan, Thailand, China, Philippines
-Africa: South Africa
For more information:
Dag Bergheim Pettersen CEO Zinzino +47 (0) 932 25 700, zinzino.com
Pictures for publication free of charge: marketing@zinzino.com
 
Certified Adviser: DNB Carnegie Investment Bank AB (publ.)
分享此页面
或复制链接